Experimental cocktail targets tough lung cancer

NCT ID NCT04631029

Completed Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a four-drug combination (entinostat, atezolizumab, carboplatin, and etoposide) in 3 people with extensive-stage small cell lung cancer that had not been treated before. The goal was to find a safe dose and see if the combination could be given for at least 3 cycles. The study is now complete, but results are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: entinostat, atezolizumab, carboplatin, etoposide
What this could lead to: If it works, this could point toward a more effective first-line treatment for extensive-stage small cell lung cancer.
What could go wrong: This is a very early phase 1 trial with only 3 participants, so safety and effectiveness are not yet established. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer cancer metastatic malignant neoplasm in the brain small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE STAGE LUNG SMALL CELL CARCINOMA MALIGNANT SOLID NEOPLASM METASTATIC MALIGNANT NEOPLASM IN THE BRAIN

Contacts and locations

Locations

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States
University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.